Eli Lilly Surpasses $500 Billion Market Cap Driven by Strong Q2 Performance and Robust Product Pipeline

On August 8, Eli Lilly and Company announced its total performance for the second quarter and the first half of 2023. The data showed that Eli Lilly's total revenue in the first half of the year was $15.272 billion, representing a year-on-year increase of 7%. Among this, the revenue for the second quarter was $8.312 billion, marking a year-on-year increase of 28%.

Driven by this catalyst, Eli Lilly's stock price surged 17%, with its market value surpassing $500 billion. This follows the company’s previous milestone in May this year when the successful Phase III study of Donanemab, a new drug for Alzheimer's disease, propelled its market value past $400 billion, once again setting a new record for the market value of a pure pharmaceutical enterprise.

Eli Lilly's sales growth in the second quarter of 2023 was mainly driven by the outstanding performance of several products, including the GLP-1R/GIPR dual agonist Mounjaro (Tirzepatide), the breast cancer drug Verzenio (Abemaciclib), the diabetes drug Jardiance (Empagliflozin), and the immunological disease drug Taltz (Ixekizumab), as well as the cash assets obtained from divesting the global rights of the nasal glucagon agonist Baqsimi to Amphastar.

Specifically, the star product Tirzepatide has seen continuous growth since its FDA approval in May 2022, with sales reaching $1.548 billion in the first half of 2023. Eli Lilly and Company expects this drug to surpass $4 billion in sales for 2023.

Thanks to the expansion of adjuvant treatment indications for breast cancer, Verzenio (abemaciclib) achieved sales of $1.678 billion in the first half of 2023, representing a 59% year-over-year increase from the first half of 2022; Jardiance (empagliflozin) reported sales of $1.246 billion in the first half of 2023, marking a 42% year-over-year growth; Taltz (ixekizumab) generated sales of $1.230 billion in the first half of 2023, reflecting a 12% year-over-year increase.

Innovent Biologics' PD-1 antibody Sintilimab generated sales of $165 million in the first half of 2023, equivalent to RMB 1.148 billion (based on the average exchange rate of 1 USD = 6.959 CNY in 2023), representing a year-on-year increase of 4%.

In terms of significant progress in the clinical pipeline, Eli Lilly resubmitted the Biologics License Application (BLA) for its new Alzheimer's drug Donanemab to the FDA in the second quarter of 2023. Feedback is expected by the end of the year. Eli Lilly also plans to submit the drug's marketing applications in other global markets, with most expected to be completed by the end of the year.

In addition, Eli Lilly announced in July the data from two Phase III studies (SURMOUNT-3 and SURMOUNT-4) of Tirzepatide, which has increased weight loss to over 26%. Eli Lilly has currently made a rolling submission to the FDA for the weight loss indication of Tirzepatide, with all application documents expected to be submitted by 2024.

Eli Lilly also updated its 2023 financial guidance in this quarterly earnings report. It increased its guidance by $22 billion, expecting total revenue for the year to reach $33.4 to $33.9 billion.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; if you need to reproduce it, please leave a message or send a notification to the WeChat Official Account's backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.